A phase II study of TKI258 (dovitinib), an oral inhibitor of FGFR3, VEGFR, and PDGFR, was recently terminated due to limited single agent activity in pretreated, advanced UC patients (NCT00790426), including in the cohort with a presumed FGFR3 mutation, despite encouraging in vitro inhibition of tumor proliferation 26. This evidence concerns the gene PDGFRB and neoplasm.